Semaglutide is a GLP-1 receptor agonist, a type of medication that mimics a hormone your gut naturally releases after eating. It slows digestion and signals your brain that you’re full, which is why it has become one of the most talked-about options in weight loss and GLP-1 telehealth today.

What semaglutide actually is

Semaglutide itself is the active ingredient. It’s sold under a few different brand names depending on the condition it’s treating:

• Ozempic is FDA-approved for type 2 diabetes.
• Wegovy is FDA-approved specifically for chronic weight management in adults with obesity, or with overweight plus a weight-related condition.

Both contain the same active ingredient at different approved uses and, often, different dosing. The FDA-approved Wegovy label states the approval covers adults with a body mass index (BMI) of 30 or higher, or a BMI of 27 or higher with a condition like high blood pressure, high cholesterol, or type 2 diabetes. That label, not general marketing language, is the actual source for who the approval is meant for.

What a Heally provider evaluates

Miracle Leaf® does not perform this evaluation. We refer you to Heally, an independent telehealth platform whose own licensed providers conduct the visit. A typical evaluation covers your health history, current medications, weight-related conditions, and whether semaglutide (or a related option like tirzepatide) is a reasonable fit for you specifically. If appropriate, the provider issues a prescription, not Miracle Leaf®.

What the evidence actually shows

A 2026 retrospective cohort study published in the journal Obesity looked at real-world outcomes for patients using semaglutide through a nationwide telehealth platform. It found a mean body weight reduction of 16.6% at 68 weeks, a result broadly consistent with the outcomes reported in the medication’s own controlled clinical trials. Women in that study saw somewhat better average outcomes than men. As with any medication, individual results vary, and side effects like nausea, diarrhea, or constipation are common, especially early on and after a dose increase.

What to expect day to day

Most telehealth semaglutide programs start at a low dose and increase it gradually over several weeks, a process called titration. This is meant to reduce side effects while your body adjusts. The most commonly reported side effects are gastrointestinal: nausea, diarrhea, vomiting, constipation, and abdominal discomfort. These tend to be most noticeable right after starting or right after a dose increase, and often ease over time. Your Heally provider will walk you through what to watch for and when to reach out, since dose adjustments and follow-up care are part of an ongoing telehealth relationship, not a one-time visit.

Cost is also part of the picture. Public self-pay pricing for semaglutide through Heally starts at $149 a month, separate from any consultation fee, according to Heally’s own published pricing as of this writing. Brand-name retail pricing without a program like this can run considerably higher. Because pricing changes, treat any specific number here as a snapshot rather than a guarantee, and confirm current terms directly with Heally before making a decision.

How this fits with other options

If you’re comparing semaglutide to other GLP-1 options, our tirzepatide page covers a dual-mechanism medication that produced higher average weight loss in head-to-head trial data, and our oral semaglutide page covers the pill-form alternative and where its FDA approval status differs from the injectable form. If cost is the deciding factor for you, our metformin page covers a lower-cost, off-label option some providers use alongside or instead of a GLP-1.

Sources

• FDA-approved label, Wegovy (semaglutide) injection, NDA 215256, June 2021 (accessdata.fda.gov)
• Tchang et al., “Real-World Evidence on Weight Loss and Safety With Semaglutide in Obesity Telehealth,” Obesity, 2026

Medically reviewed by REVIEW LATER - named medical reviewer pending. Last reviewed 2026-07-23.